23. Apr. 2025St. Gallen International Breast Cancer Conference 2025
Moderne Brustkrebsbehandlung: Fortschritt und Preis
Die systemische Therapie bei Brustkrebs hat in den letzten Jahren enorme Fortschritte gemacht. Moderne zielgerichtete Behandlungen und Biomarker-basierte Strategien eröffnen neue Perspektiven, stellen aber zugleich hohe Anforderungen an Praxis, Patientensicherheit und Gesundheitssysteme. Wie gelingt der Weg von der Studie zur alltagstauglichen Therapie?
LASZLO/stock.adobe.com
Die Entwicklung der systemischen Therapie in den letzten Jahren hat die Behandlungsergebnisse zweifelsohne verbessert. Vor 15 Jahren waren die Therapiemöglichkeiten für eine ansonsten gesunde prämenopausale Patientin mit Brustkrebs Grad 3 auf AC-T-Chemotherapieprotokolle und Tamoxifen beschränkt. Heute stehen mehr zielgerichtete Therapien wie Pembrolizumab, Capecitabin, Olaparib, CDK4/6-Inhibitoren, Ovarialsuppression (OFS) und Aromatasehemmer (AIs) zur Verfügung.
Referenzen
- Goddard, K. A. B. et al. Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020. JAMA Oncol. 2025 Feb 1;11(2):162-167. doi: 10.1001/jamaoncol.2024
- Cherny, N. I. et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol. 2017 Oct 1;28(10):2340-2366. doi: 10.1093/annonc/mdx310
- Kalinsky, K. et al. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. J Clin Oncol. 2025 Mar 20;43(9):1101-1112. doi: 10.1200/JCO-24-02086
- Fasching, P. A. et al. LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial. Annals of Oncology. 2024;35(2):S1207. doi: 10.1016/j.annonc.2024.08.2251
- Geyer, C. E. et al. Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer. N Engl J Med. 2025 Jan 16;392(3):249-257. doi: 10.1056/NEJMoa2406070
- Geyer, C. E. et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022 Dec;33(12):1250-1268. doi: 10.1016/j.annonc.2022.09.159
- Schmid, P. et al. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med. 2024 Nov 28;391(21):1981-1991. doi: 10.1056/NEJMoa2409932
- Jayan, A. et al. Real-World Immune-Related Adverse Events in Patients With Early Triple-Negative Breast Cancer Who Received Pembrolizumab. JCO Oncol Pract. 2024 Oct 10:OP2400371. doi: 10.1200/OP.24.00371
- Marhold, M. et al. Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer. Oncoimmunology. 2023 Nov 13;12(1):2275846. doi: 10.1080/2162402X.2023.2275846
- Aoyama, Y. et al. Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study. Breast Cancer. 2025 Mar;32(2):329-336. doi: 10.1007/s12282-024-01657-4
- Patrinely, J. R. et al. Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma. JAMA Oncol. 2021 May 1;7(5):744-748. doi: 10.1001/jamaoncol.2021.0051
- Güven, D. C., Thong, M. S. & Arndt, V. Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review. J Cancer Surviv. 2024 Jan 4. doi: 10.1007/s11764-023-01507-w
- Cronin, C., O’Sullivan, A. & Naidoo, J. Long-Term Toxicity of Immune Checkpoint Inhibitors—Time to Widen the Lens. JAMA Oncol. 2025 Feb 27. doi: 10.1001/jamaoncol.2024.6809
- Natarajan, A. & Tolaney, S. M. Is adjuvant ribociclib ready for prime time? Ann Oncol. 2024 Dec;35(12):1200-1201. doi: 10.1016/j.annonc.2024.08.2341
- Prat, A. et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2020 Jan;21(1):33-43. doi: 10.1016/S1470-2045(19)30786-7